Document Detail


Novel synthetic small-molecule activators of AMPK as enhancers of autophagy and amyloid-β peptide degradation.
MedLine Citation:
PMID:  20852062     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AMP-activated protein kinase (AMPK) is a metabolic sensor involved in intracellular energy metabolism through the control of several homeostatic mechanisms, which include autophagy and protein degradation. Recently, we reported that AMPK activation by resveratrol promotes autophagy-dependent degradation of the amyloid-β (Aβ) peptides, the core components of the cerebral senile plaques in Alzheimer's disease. To identify more potent enhancers of Aβ degradation, we screened a library of synthetic small molecules selected for their structural similarities with resveratrol. Here, we report the identification of a series of structurally related molecules, the RSVA series, which inhibited Aβ accumulation in cell lines nearly 40 times more potently than did resveratrol. Two of these molecules, RSVA314 and RSVA405, were further characterized and were found to facilitate CaMKKβ-dependent activation of AMPK, to inhibit mTOR (mammalian target of rapamycin), and to promote autophagy to increase Aβ degradation by the lysosomal system (apparent EC(50) ∼ 1 μM). This work identifies the RSVA compounds as promising lead molecules for the development of a new class of AMPK activating drugs controlling mTOR signaling, autophagy, and Aβ clearance.
Authors:
Valérie Vingtdeux; Pallavi Chandakkar; Haitian Zhao; Cristina d'Abramo; Peter Davies; Philippe Marambaud
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural     Date:  2010-09-17
Journal Detail:
Title:  FASEB journal : official publication of the Federation of American Societies for Experimental Biology     Volume:  25     ISSN:  1530-6860     ISO Abbreviation:  FASEB J.     Publication Date:  2011 Jan 
Date Detail:
Created Date:  2011-01-05     Completed Date:  2011-03-08     Revised Date:  2014-09-22    
Medline Journal Info:
Nlm Unique ID:  8804484     Medline TA:  FASEB J     Country:  United States    
Other Details:
Languages:  eng     Pagination:  219-31     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
AMP-Activated Protein Kinases / genetics,  metabolism*
Amyloid beta-Peptides / genetics,  metabolism*
Animals
Anti-Inflammatory Agents, Non-Steroidal / chemistry,  pharmacology
Autophagy / drug effects*
Cell Line, Tumor
Cell Survival / drug effects
Cells, Cultured
Dose-Response Relationship, Drug
Enzyme Activation / drug effects
Enzyme Activators / chemical synthesis,  chemistry,  pharmacology*
Female
HEK293 Cells
Humans
Lysosomes / drug effects,  metabolism
Mice
Mice, Inbred C57BL
Molecular Structure
Stilbenes / chemistry,  pharmacology
TOR Serine-Threonine Kinases / metabolism
Transfection
Grant Support
ID/Acronym/Agency:
P01 AT004511/AT/NCCAM NIH HHS; R37 AG022102/AG/NIA NIH HHS; R37 AG022102-09/AG/NIA NIH HHS; UL1-RR024996/RR/NCRR NIH HHS
Chemical
Reg. No./Substance:
0/Amyloid beta-Peptides; 0/Anti-Inflammatory Agents, Non-Steroidal; 0/Enzyme Activators; 0/Stilbenes; EC 2.7.1.1/TOR Serine-Threonine Kinases; EC 2.7.11.1/AMP-Activated Protein Kinases; Q369O8926L/resveratrol
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Exercise training in older patients with heart failure and preserved ejection fraction: a randomized...
Next Document:  Efficient nonadhesive ex vivo expansion of early endothelial progenitor cells derived from CD34+ hum...